Skip to main content
Premium Trial:

Request an Annual Quote

Atlas Venture Raises $950 Million For Venture Capital Fund

NEW YORK, April 26 - Atlas Venture has raised $950 million from institutional investors to start a new capital fund that will invest in early-stage communications, information technology, and life science companies, the venture capital firm said Thursday.

The new fund, called Atlas Venture VI, will invest in both US and European early-stage companies, and will likely divide funding equally between the three business sectors, said a spokeswoman for Atlas Venture.

In the past, Atlas has invested in life science companies such as DeCode Genetics, Ciphergen Biosystems, Structural Genomix, and Signature Bioscience.

Atlas is also currently raising money to establish a parallel fund for entrepreneurs and other individual investors, to invest alongside the main fund. Together the two funds will have a total value just shy of $1 billion, the spokeswoman said.

The fund is the sixth for 21-year old Atlas Venture, which has over $2.5 billion in committed capital in 300 companies.  
The Scan

Highly Similar

Researchers have uncovered bat viruses that are highly similar to SARS-CoV-2, according to Nature News.

Gain of Oversight

According to the Wall Street Journal, the Biden Administration is considering greater oversight of gain-of-function research.

Lasker for mRNA Vaccine Work

The Scientist reports that researchers whose work enabled the development of mRNA-based vaccines are among this year's Lasker Award winners

PLOS Papers on Causal Variant Mapping, Ancient Salmonella, ALK Fusion Test for NSCLC

In PLOS this week: MsCAVIAR approach to map causal variants, analysis of ancient Salmonella, and more.